611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
New Data Shows the Power of COVID VaccinesTroubling Rise Seen in Both COVID, RSV Cases Among ChildrenTake This Refresher on Skin Safety in Summer SunAll Sunglasses Not Equal When it Comes to Eye ProtectionTeens' Heart Risk From COVID Far Exceeds That of Vaccination: StudyCould COVID-19 Accelerate Alzheimer's Symptoms?New Data Details Dangers of Delta Variant, Even for the VaccinatedCDC Now Says Vaccinated Should Be Tested After COVID Exposure, Even Without SymptomsWhy Strokes Can Affect Women, Men DifferentlyMore Than Half of Americans Plagued by Back, Leg PainPfizer Says 3rd Shot of Vaccine Boosts COVID ProtectionVitamin D May Lower Black Women's Odds for COVID-19Primary Care Doctors Often Miss Heart Failure in Women, Black PatientsBogus Info on Cancer Common Online, and It Can HarmDelta Variant Spreads More Easily, Causing CDC Change on Indoor MaskingSevere COVID for People Under 45: Who's Most at Risk?The Heat Is On: Staying Safe When Temperatures SoarWho's Most Likely to Refuse a COVID Vaccine?Second COVID Shot Safe in Folks Who Had Allergic Reaction to FirstHigh Blood Pressure: Which Drug Works Best for You?Pfizer, Moderna to Expand Vaccine Studies in Young ChildrenFederal, State Moves Begin to Mandate COVID Vaccines for WorkersCan COVID Transmit Easily on Crowded School Buses?Worried About Delta-Linked 'Breakthrough' Infections? Experts Explain the RisksMajor Medical Groups Call for Mandatory COVID Vaccination for Health WorkersU.S. to Stick With International Travel RestrictionsSurvey Finds U.S. Parents Split on COVID Vaccination for Kids Under 12Most Unvaccinated Americans Want to Stay That Way: PollIt's Tick Season: Protect Yourself From Lyme DiseaseHigh-Tech Exoskeletons Improve Bowel Function in People With Spinal Cord Injury'Superbug' Fungus Spreads Among Vulnerable in Two U.S. CitiesVaccinations Start to Climb in States Hit Hard by Delta VariantAs Olympics Begin, Tokyo Posts Highest Number of New COVID Cases in Six MonthsVirtual Roller Coaster Ride Study Brings New Insights Into MigraineBiden Says Full Approval for COVID Vaccines Coming SoonPfizer Vaccine Offers 88% Protection Against Delta Variant, But 2 Doses NeededSecret Weapon: Why the 2nd Dose of Pfizer Vaccine Is So CrucialIn a First for the Continent, Pfizer COVID-19 Vaccine Will Be Produced in South AfricaLockdowns' Effects on Health Still Less Than Harm From Pandemic: ExpertsCOVID Drove Biggest Drop in U.S. Life Expectancy Since World War IIJ&J Vaccine Weak Against Delta Variant, 2nd Dose May Be NeededDouble Trouble: Wildfire Smoke Could Boost Odds for COVID's SpreadStatin Users May Have Added Protection Against Severe COVID-19Severe COVID in Kids: Rare, but Brain Issues Can ResultOne-Dose Blood Thinner Could Slash Blood Clot Risk After Knee ReplacementU.S. Issues Toughest Travel Alert for Britain As COVID Cases There ClimbPediatricians' Group: All School Kids, Staff Should Continue to Wear MasksGeneticists Probe Origins of Painful Cluster HeadachesAny COVID Infection Leaves Strong Antibody Levels in KidsMany Hit Hard by Pandemic Now Swamped by Medical Debt
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

WHO Says No to Remdesivir as COVID-19 Treatment

HealthDay News
by Robert Preidt
Updated: Nov 20th 2020

new article illustration

FRIDAY, Nov. 20, 2020 (HealthDay News) -- The antiviral drug remdesivir is not recommended for hospitalized COVID-19 patients because there's no evidence that it reduces their need for ventilation or improves their chances of survival, a World Health Organization panel said Thursday.

Remdesivir is regarded as a potential treatment for severe COVID-19 and is used to treat hospitalized patients, but there is uncertainty about its effectiveness. Nevertheless, the U.S. Food and Drug Administration approved the drug to treat hospitalized COVID-19 patients in October.

In the new assessment, the WHO panel of experts analyzed data from four international randomized trials that assessed several treatments for COVID-19 and included more than 7,000 hospitalized COVID-19 patients.

The panel -- which included four people who've had COVID-19 -- concluded that remdesivir has no meaningful impact on the risk of death or any other important patient outcomes, such as the need for mechanical ventilation or how long it takes for their condition to improve.

The results of the trials don't prove that remdesivir has no benefit. Instead, they provide no evidence that the drug improves patient outcomes, the panel explained in an article published Nov. 19 in the BMJ medical journal.

However, given the risk of significant harm, the relatively high cost, and the demands on health care staff (remdesivir must be given intravenously), their recommendation is appropriate, the panel said.

The panel also said they support continued enrollment into trials evaluating the use of remdesivir in COVID-19 patients, especially to provide more reliable evidence for specific groups of patients.

The future use of remdesivir in treating COVID-19 patients is unclear, given that it's unlikely to be the lifesaving drug many have hoped for, American journalist Jeremy Hsu wrote in a linked article in the journal.

He also noted that alternative treatments -- such as the inexpensive and widely available corticosteroid dexamethasone, which has been shown to reduce death risk in severely ill COVID-19 patients -- are now part of the discussions about remdesivir's worth as a COVID-19 treatment.

"It's become clear that remdesivir, at best, has a marginal benefit if any on clinical improvement," said Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security in Baltimore. "It is not surprising, therefore, that the WHO guideline committee does not support its use, underscoring the need for better treatments that more meaningfully impact patient outcomes."

More information

For more on treatments for severe COVID-19, go to the U.S. Centers for Disease Control and Prevention.


SOURCES: BMJ, news release, Nov. 19, 2020; Amesh Adalja, MD, senior scholar, Johns Hopkins Center for Health Security, Baltimore